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ÖZET
Amaç: Bu çalışmanın amacı, klinik örneklerden izole edi-
len stafilokok suşlarında fusidik asidin in vitro etkinliğinin 
araştırılmasıdır.
Gereç ve yöntem: Çalışmaya çeşitli klinik örneklerden 
izole edilen 41 koagülaz negatif stafilokok (KNS) izolatı 
ile 18 Staphylococcus aureus suşu dahil edildi. Stafilo-
kok izolatları besiyeri yüzeyindeki koloni morfolojisi, gram 
boyama, katalaz ve koagülaz testleri gibi konvansiyonel 
yöntemlerle identifiye edildi. İzolatların antimikrobiyal du-
yarlılıkları  “Clinical  and  Laboratory  Standards  Institute 
(CLSI)” önerileri doğrultusunda Kirby-Bauer disk difüzyon 
yöntemi kullanılarak çalışıldı.
Bulgular: İzole edilen S.aureus suşlarının % 72’si metisi-
line duyarlı (MSSA), % 28’i metisiline dirençli (MRSA) ola-
rak tanımlandı. MSSA ve MRSA suşlarının fusidik asit du-
yarlılık oranları arasındaki fark istatistiksel olarak anlamlı 
bulunmadı (p=0.305). İzole edilen KNS’lerin % 29’u me-
tisiline duyarlı (MS-KNS), % 71’i metisiline dirençli (MR-
KNS) olarak tanımlandı. MR-KNS ve MS-KNS suşlarının 
fusidik asit duyarlılık oranları arasında istatistiksel olarak 
anlamlı fark yoktu (p=0.490). Ancak, KNS ve S.aureus 
suşlarının fusidik asit duyarlılık oranları arasındaki fark is-
tatistiksel olarak anlamlıydı (p<0.001). KNS suşları fusidik 
aside S.aureus suşlarından daha fazla dirençli bulundu.
Sonuç: Bu çalışmada, metisilin direnci ile birlikte fusidik 
aside karşı da direnç gelişiminde artış olduğu gözlendi. 
KNS  izolatları  arasındaki  fusidik  aside  direnç  oranları 
S.aureus suşlarına göre önemli ölçüde artmıştır. Sonuç 
olarak, fusidik asit stafilokoklara bağlı enfeksiyonların te-
davisinde hala bir alternatif olarak durmaktadır.
Anahtar kelimeler: Staphylococcus aureus, fusidik asit, 
mikrobiyal duyarlılık testi
ABSTRACT
Objectives: The aim of this study was to investigate in vi-
tro susceptibility of fusidic acid to clinic isolates of staphy-
lococci.
Materials and methods: The forty-one coagulase nega-
tive staphylococci (CNS) and 18 Staphylococcus aureus 
strains isolated from various clinical specimens were in-
cluded in this study. Staphylococci isolates were identi-
fied by conventional methods such as colony morphol-
ogy onto medium, gram staining, catalase and coagulase 
tests. According to “Clinical and Laboratory Standards In-
stitute (CLSI)” criteria, antimicrobial susceptibility testing 
of isolates was performed by Kirby-Bauer’s disk diffusion 
method.
Results: The seventy-two percent of the isolated S.aureus 
were defined as methicillin sensitive-S.aureus (MSSA), 
28% of the isolated S.aureus were defined as methicillin 
resistant-S.aureus (MRSA). The difference among fusidic 
acid susceptibility rates of MSSA and MRSA strains was 
not statistically significant (p=0.305). The twenty-nine per-
cent of the isolated CNS were defined as methicillin sen-
sitive-CNS (MS-CNS), 71% of the isolated CNS were de-
fined as methicillin resistant-CNS (MR-CNS). There was 
no  statistically  significant  difference  between  MS-CNS 
and MR-CNS strains for fusidic acid susceptibility rates 
(p=0.490). But the difference among fusidic acid suscep-
tibility rates of CNS and S.aureus strains was statistically 
significant (p<0.001). CNS strains were found more resis-
tance than S.aureus strains for fusidic acid.
Conclusion:  In  this  study,  the  resistance  rates  were 
detected to increase for fusidic acid along with methicil-
lin  resistance. Among  CNS  isolates,  fusidic  acid  resis-
tance rates were significantly more elevated than that for 
S.aureus. Fusidic acid remains as an alternative in the 
treatment of infections due to staphylococci.
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INTRODUCTION
Fusidic acid is an antimicrobial drug obtinated from 
Fusidium coccineum.1 Since being made available 
for clinical use in 1960s, fusidic acid has been uti-
lized in Europe and Australia for the treatment of 
staphylococcal infections. During the early develop-
ment of this antimicrobial drug, resistance appeared 
to be selected easily in vivo and in vitro; but data 
from countries where fusidic acid was used in logi-
cal quantities showed that resistance rates stayed 
modest and that staphylococci showing elevated fu-
sidic acid minimum inhibitory concentration (MIC) 
values hadn’t emerged rapidly.2
Fusidic  acid  inhibits  protein  synthesis  by 
blocking the elongation of the nascent polypeptide 
chain through binding to EFG on the ribosome and 
preventing the dissociation of EFG-GDP from the 
ribosome.3,4 The rate of fusidic acid resistance isn’t 
very high; but the existence of clinical staphylococ-
cal species that are resistant to fusidic acid has been 
reported.5
In present study, in vitro susceptibilities of a 
variety of staphylococci strains isolated from clini-
cal specimens to fusidic acid were investigated.
MATERIALS AND METHODS
Bacterial isolates
From April 2009 to August 2011, 41 coagulase neg-
ative staphylococci (CNS) and 18 coagulase posi-
tive S.aureus strains isolated from various clinical 
specimens that had been sent to microbiology labo-
ratory of Kızıltepe General Hospital had been in-
cluded in this study. S.aureus ATCC 29213 has con-
sistently been used as a quality control strain. 5% 
sheep  blood  agar  (Oxoid  Ltd.,  Basingstoke,  UK) 
medium was used for bacterial growth at 35±2°C 
with aeration for 18-24 hours. Mueller-Hinton agar 
(Oxoid Ltd., Basingstoke, UK) medium was used 
for all determinations of Kirby-Bauer’s disk diffu-
sion method. All isolates were identified by con-
ventional methods such as colony morphology onto 
medium, gram staining, catalase and coagulase re-
actions.
Antimicrobial susceptibility testing
Methicillin resistance was determined by incuba-
tion of oxacillin (1 μg) disk onto Mueller-Hinton 
agar medium aerobically at 35±2°C for 18-24 hours. 
Oxacillin inhibition zone diameter >13 mm were 
evaluated as susceptible, <10 mm were resistant. 
Antimicrobial susceptibility testing was performed 
by Kirby-Bauer’s disk diffusion method in accor-
dance with the recommendations of CLSI.6
For fusidic acid, where CLSI does not provide 
disk susceptibility breakpoints, the required diam-
eters for sensitivity and resistance were ≥22 mm 
and <22 mm, respectively (10 μg fusidic acid disk) 
according to the European Committee on Antimi-
crobial  Susceptibility  Testing  (EUCAST)  clinical 
breakpoints.7  However,  in  this  study  fusidic  acid 
susceptibility was detected according to the criteria 
of Comite de L’antibiogramme de la Societe Fran-
çaise de Microbiologie, and inhibition zone of ≥22 
mm was considered as sensitive, 16-21 mm as inter-
mediate, ≤15 mm as resistant.
Statistical analysis
Data of this study were analyzed by Epi InfoTM 
7-Community Edition (Centers for Diseases Con-
trol and Prevention, Atlanta, GA, USA) statistical 
package program. Statistical evaluation of differ-
ence between MR-CNS and MS-CNS strains, be-
tween MSSA and MRSA strains, between CNS and 
S.aureus strains for fusidic acid susceptibility was 
performed with the Fisher’s Exact test. The p value 
of <0.05 was selected for statistical significance.
RESULTS
The eighty-nine percent of S.aureus strains and 39% 
of CNS strains were found as sensitive to fusidic 
acid. Fusidic acid susceptibility rates of staphylo-
cocci strains were shown on Table 1. The differ-
ence among fusidic acid susceptibility rates of CNS 
and  S.aureus  strains  was  statistically  significant 
(p<0.001). CNS strains were found more resistance 
than S.aureus strains for fusidic acid.
The  seventy-two  percent  of  the  isolated 
S.aureus were defined as MSSA, 28% of the isolat-
ed S.aureus were defined as MRSA. Resistance to 
fusidic acid was observed in 20% (1 of 5) of MRSA 
isolates and 8% (1 of 13) of MSSA. The difference 
among  fusidic  acid  susceptibility  rates  of  MSSA 
and MRSA strains was not statistically significant 
(p=0.305) (Table 2).T. T. Özer et al. Fusidic acid resistance among staphylococci 3
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The twenty-nine percent of the isolated CNS 
were defined as MS-CNS, 71% of the isolated CNS 
were defined as MR-CNS. While 45% of MR-CNS 
was resistant to fusidic acid, fusidic acid resistance 
was found to be 25% in MS-CNS. There was no 
statistically significant difference between MS-CNS 
and MR-CNS strains for fusidic acid susceptibility 
rates (p=0.490) (Table 3).
Table 1. Fusidic acid susceptibility rates of staphylococci 
strains.
Bacteria S n (%) R n (%) p
S.aureus (n=18) 16 (89) 2 (11) <0.001
CNS (n=41) 16 (39) 25 (61)
S: sensitive; R: resistant
Table 2. Fusidic acid susceptibility rates of CNS strains.
Bacteria S n (%) R n (%) p
CNS (n=41) MS-CNS (n=12) 3 (25) 9 (75) 0.305
MR-CNS (n=29) 13 (45) 16 (55)
S: sensitive; R: resistant
Table 3.  Fusidic  acid  susceptibility  rates  of  S.aureus 
strains.
Bacteria S n (%) R n (%) p
S.aureus (n=18) MSSA (n=13) 12 (92) 1 (8) 0.490
MRSA (n=5) 4 (80) 1 (20)
S: sensitive; R: resistant
DISCUSSION
Fusidic  acid  is  used  in  European  Countries  and 
Australia for a long time. It has also been used in 
other countries, except in the United States in recent 
years. Fusidic acid resistance has developed slowly, 
and the level of resistance and genetic mechanisms 
responsible generally reflect the time since intro-
duction,  indications  for  treatment,  administration 
route, and prescribing practices widely throughout 
the world.8
Fusidic  acid  resistance  has  increased  among 
S.aureus strains, including MRSA in the past twen-
ty years. But, there are limited data concerning the 
relative importance in this process of the different 
staphylococcal determining factors that mediate re-
sistance to fusidic acid. Moreover, the roles played 
by  clonal  dissemination  of  fusidic  acid-resistant 
strains  versus  horizontal  transmission  of  fusidic 
acid resistance determining factors have not been 
examined in detail.9
Previous studies related with fusidic acid re-
sistance in strains isolated from clinical specimens 
have mainly focused on MSSA and other staphylo-
cocci.5 Chen et al. recently reported that the preva-
lence  of  fusidic  acid-resistance  determinants  was 
quite different between MRSA and MSSA groups.10
In spite of fusidic acid has been used on the 
world in recent ten years, has never been accepted 
in the United States. MRSA, with a long safety re-
cord has a great need for an oral MRSA antibiotic 
at the present time. In USA some drug companies 
worked to allow market exclusivity when this an-
tibiotic  is  approved  in  the  United  States. A  new 
dose arrangement that allowing fusidic acid to be 
used as monotherapy has been accepted, and it has 
been  shown  that  fusidic  acid  resistance  rates  are 
reduced selectivity.11 Fusidic acid resistance rates 
were lowest in the United States, where fusidic acid 
is not used routinely in clinical treatment. Also re-
sistance rates were low in Australia and Canada, 
where fusidic acid has been used as drug for more 
than twenty years, the data were not especially el-
evated in Australia and Canada. This observation 
is in accordance with other reports that also noted 
that  emergence  of  fusidic  acid  resistance  hasn’t 
been rapid, although its clinical use and show that 
this antimicrobial agent still provides a potentially 
useful  treatment  option  for  infections  caused  by 
multidrug-resistant  gram-positive  isolates  (99.7% 
susceptibility  among  S.aureus  strains),  including 
MRSA strains. Fusidic acid resistance was viewed 
more frequently among MSSA isolates than among 
methicillin-resistant strains in the United States (0.6 
and  0.1%,  respectively).  Conversely,  fusidic  acid 
resistance was higher among MR-CNS isolates than 
among MS-CNS isolates (9.2 and 5.2% for MR-
CNS and MS-CNS, respectively). Fusidic acid re-
sistance rate has not evaluated for Canada and Aus-
tralia because of the decreased numbers of strains 
included in study. Moreover, 36.0% of the fusidic 
acid resistant S.aureus strains has got also methicil-
lin resistance. Occurrence rates of fusidic acid resis-
tance among S.aureus (0.3%) and CNS (7.2%) iso-
lates were notably lower in the United States than in 
other two countries analyzed. S.aureus strains with 
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common in Australia than in Canada (7.0% for both 
countries), but the CNS resistance rates were differ-
ent, with resistance being more common in Canada 
(20.0% versus 10.8% in Australia).2
In our country several studies have been done 
about fusidic acid resistance related to staphylococ-
ci (Table 4).
Table 4. Fusidic acid resistance rates of staphylococcal 
strains isolated in our country, in some studies.
Year MSSA MRSA MS-CNS MR-CNS
Erdemoğlu et al.15 2000 3.2 7.7 10.8 14.9
Altun et al.16 2003 0 3 0 13
Şengöz et al.17 2004 1 9 21 33
Celen et al.18 2005 3 6 20 3
Nergiz et al.19 2007 - - - 28
Ekşi et al.20 2008 2.4 9.2 - -
Mert Dinç et al.21 2009 - 1.4 - -
Yaman et al.22 2010 4 6 - -
Deveci et al.23 2011 4 1 14 8
MSSA: methicillin sensitive S.aureus, MRSA: methicillin 
resistant S.aureus
MS-CNS: methicillin sensitive coagulase negative staph-
ylococcus
MR-CNS: methicillin resistant coagulase negative staphy-
lococcus
Keşli et al.12 reported that 63% of S.aureus 
and 50 (66%) of CNS strains were methicillin resis-
tant. Two (7%) of MRSA strains, 1 (6%) of MSSA 
strains, 16 (32%) of MR-CNS strains and 3 (12%) 
of MS-CNS strains were found to be resistant to fu-
sidic acid. They indicated that fusidic has not to be 
excluded in preference of the antibiotic treatment of 
staphylococcal infections.
Kuzucu et al.13 investigated in vitro activity 
of fusidic acid in 112 MRSA and MR-CNS by disk 
diffusion and microdilution methods. 4% of MRSA 
and 27% MR-CNS were found to be resistant to fu-
sidic acid.
In a study of Uluğ et al.14 resistance to fusid-
ic acid has been found as 4.3% in MSSA strains, 
16.7% in MRSA strains, 0% in MS-CNS, 36% in 
MR-CNS, however in none of the strains vancomy-
cin, and teicoplanin resistance have been observed.
In conclusion, the present study is in accordance 
with other reports that also noted that emergence of 
fusidic acid resistance has not been rapid, despite its 
clinical use, and demonstrates that this antimicrobi-
al agent still provides a potentially useful treatment 
option for infections caused by multidrug-resistant 
gram-positive isolates, including MRSA strains.
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